Depressive patients who took escitalopram after acute coronary syndrome (ACS)-related events had lower reoccurrences of major adverse cardiac events after eight years of follow-up, a group of Korean researchers reported in the Journal of the American Heart Association.

Abbott announced it will conduct a pivotal clinical study in the U.S. of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, for the treatment of mitral regurgitation (MR).

Twice as many U.S. deaths due to cardiac amyloidosis were reported in 2015 than in 1979, but a study in JAMA Cardiology suggests the disease remains vastly underdiagnosed.

Australian women with the deadliest type of heart attack, ST-segment elevation myocardial infarction (STEMI), are less likely to receive invasive treatment, revascularization or preventive medication at discharge, researchers reported in the Medical Journal of Australia.

A calcium-channel blocker delivered as a nasal spray rapidly restored individuals with paroxysmal supraventricular tachycardia (SVT) to normal sinus rhythm in a phase 2 study, raising the possibility that the drug could be self-administered in a real-world setting and prevent trips to the emergency department.

Having a multidisciplinary team available around-the-clock to meet patients with suspected emergent large vessel occlusion (ELVO) strokes helped a hospital achieve median door-to-recanalization times of 52 minutes, according to a study presented at the Society of NeuroInterventional Surgery’s annual meeting.

Harvard University bioengineers have created a 3D model of a human’s left ventricle that they believe could be used to test drugs and study diseases.

Stroke rates are higher in the first 30 days after coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI) but are similar thereafter, according to a pooled analysis of 11 randomized trials published July 16 in the Journal of the American College of Cardiology.